Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 9 · below the Ichimoku cloud · RSI 35 · MACD below its signal · 8% above its 52-week low
| 8.48 | 52-week high | +132.97% |
| 5.11 | Previous month high | +40.25% |
| 4.12 | Previous week high | +13.19% |
| 4.10 | R3 (classic) | +12.73% |
| 4.07 | Previous month low | +11.68% |
| 3.91 | R2 (classic) | +7.33% |
| 3.77 | R1 (classic) | +3.66% |
| 3.71 | Previous day high | +1.92% |
| 3.64 | Price now | |
| 3.60 | Previous week low | −1.10% |
| 3.58 | Pivot | −1.74% |
| 3.44 | S1 (classic) | −5.40% |
| 3.38 | Previous day low | −7.14% |
| 3.38 | 52-week low | −7.14% |
| 3.25 | S2 (classic) | −10.81% |
| 3.11 | S3 (classic) | −14.47% |
None of the 29 investors followed here reported a position in IMRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IMRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 22, 2026 | Zeskind Benjamin JChief Executive Officer | Purchase at price 4.56 per share. | 2.4K | $10.95K |
| Jun 14, 2026 | Hall Brett MatthewOfficer | Purchase at price 4.15 per share. | 6K | $25.05K |
| Mar 12, 2026 | Neufeld Leah ROfficer | Stock Award(Grant) at price 4.29 per share. | 3.6K | $15.57K |
| Jan 15, 2026 | Brakewood Harold EugeneOfficer | Purchase at price 4.76 per share. | 5.3K | $24.99K |
| Jan 14, 2026 | Schall Thomas JDirector | Purchase at price 4.67 per share. | 21.6K | $101.04K |
| Jan 14, 2026 | Hall Brett MatthewOfficer | Purchase at price 4.57 per share. | 2.3K | $10.50K |
| Jan 12, 2026 | Neufeld Leah ROfficer | Purchase at price 4.15 per share. | 2.6K | $10.91K |
| Jan 11, 2026 | Feinberg PeterDirector | Purchase at price 4.35 per share. | 20K | $86.90K |
| Oct 2, 2025 | Feinberg PeterDirector | Purchase at price 6.67 per share. | 7.5K | $50.02K |
| Sep 30, 2025 | Bookman MichaelOfficer | Purchase at price 6.83 per share. | 1K | $6.97K |
| Sep 30, 2025 | Morales MalloryOfficer | Purchase at price 6.39 per share. | 300 | $1.92K |
| Sep 30, 2025 | Neufeld Leah ROfficer | Purchase at price 6.38 per share. | 800 | $5.10K |
| Sep 29, 2025 | Feinberg PeterDirector | Purchase at price 7.03 per share. | 7.5K | $52.73K |
| Sep 28, 2025 | Feinberg PeterDirector | Purchase at price 7.18 per share. | 5K | $35.90K |
| Sep 14, 2025 | Hall Brett MatthewOfficer | Stock Award(Grant) at price 7.86 per share. | 14.9K | $116.96K |
| Sep 14, 2025 | Morales MalloryOfficer | Stock Award(Grant) at price 7.86 per share. | 14.5K | $113.95K |
| Sep 14, 2025 | Neufeld Leah ROfficer | Stock Award(Grant) at price 7.86 per share. | 11.8K | $92.87K |
| Jul 1, 2025 | Hausman DianaDirector | Purchase at price 3.60 - 3.62 per share. | 5.5K | $19.86K |
| Jul 1, 2025 | Zeskind Benjamin JChief Executive Officer | Purchase at price 3.38 - 3.53 per share. | 10K | $34.88K |
| Jul 1, 2025 | Neufeld Leah ROfficer | Purchase at price 3.57 per share. | 700 | $2.50K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -29.6 | 7.8 | 5.6 | -0.6 | 10.1 | -13.5 | -17.2 | 20.8 | -17.9 | -11.1 | −44.7% | ||
| 2025 | -11.8 | -14.9 | -7.9 | -21.7 | 43.7 | 97.1 | 2.1 | 67.2 | 21.7 | -1.9 | 11.5 | -14.1 | +199.1% |
| 2024 | -20.1 | 5.6 | -53.4 | -50.9 | -2.1 | -7.9 | -11.7 | -1.8 | 124.3 | -25.3 | 12.4 | 5.3 | −70.1% |
| 2023 | -13.6 | 16.7 | 98.6 | 13.1 | -29.4 | 30.8 | 0.2 | -11.3 | -14.8 | -8.5 | -6.7 | 12.0 | +51.5% |
| 2022 | -38.2 | -25.3 | -13.4 | -23.2 | -9.9 | 20.8 | 20.5 | -14.4 | 156.6 | -3.3 | -53.1 | -25.3 | −70.0% |
| 2021 | 39.1 | 8.5 | 2.1 | -16.5 | -28.5 | −8.1% |
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Buy / hold / sell counts